RYTM stock news today

Guggenheim kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $147.

Citizens JMP kept its Market Outperform rating on Rhythm Pharmaceuticals (RYTM) and raised its price target to $166 from $160.

Needham kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $114.

William Blair started coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating.

J.P. Morgan kept its Overweight rating on Rhythm Pharmaceuticals (RYTM) and lowered its price target to $145 from $146.

HC Wainwright & Co. kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $130.

RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals (RYTM) and raised its price target to $159 from $155.

Deutsche Bank started coverage of Rhythm Pharmaceuticals (RYTM) with a Hold rating and a price target of $120.

What is the latest news on RYTM?

Nov 5, 2026: Guggenheim kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $147. (Guggenheim) · Nov 4, 2026: Citizens JMP kept its Market Outperform rating on Rhythm Pharmaceuticals (RYTM) and raised its price target to $166 from $160. (Citizens JMP) · Nov 3, 2026: Needham kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $114. (Needham)

What are analysts saying about RYTM?

Nov 5, 2026: Guggenheim kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $147. · Nov 4, 2026: Citizens JMP kept its Market Outperform rating on Rhythm Pharmaceuticals (RYTM) and raised its price target to $166 from $160. · Nov 3, 2026: Needham kept its Buy rating on Rhythm Pharmaceuticals (RYTM) with a price target of $114.